

Press release

DiagnOptics receives CE mark approval for Diab-spot.

Groningen, the Netherlands – December 16, 2011

DiagnOptics receives CE mark approval for their latest product, Diab-spot. Diab spot is a non-invasive test to identify people at risk for diabetes or pre-diabetes . The CE mark allows DiagnOptics to market Diab-spot in the European Union.

DiagnOptics was the first company worldwide to introduce a technology to noninvasively measure the tissue accumulation of AGEs by means of fluorescence techniques (AGE Reader). Diab-spot features this AGE measurement and combines this with a small number of patient characteristics to calculate the Diab-spot test result. These simple characteristics include questions about other well-known diabetes risk factors , which can be easily answered on the touch screen. Diab-spot yields an immediate screening result on the spot.

The detection of (pre-)diabetes patients by Diab-spot is superior to FPG and HbA1c. In a multi-center clinical study in the Netherlands, both sensitivity and specificity of Diab-spot were significantly better than FPG and HbA1c.

[Read more](#)

About DiagnOptics

DiagnOptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader - a state of art diagnostic device that can determine the tissue accumulation of AGEs in 30 seconds. Since the CE certification on the AGE Reader in 2006, DiagnOptics has been marketing this medical device to hundreds of clinics around the world. Currently the company is working on obtaining additional regulatory approvals in other regions and is engaged in new product development activities. The head office of DiagnOptics Technologies BV is in Groningen, the Netherlands.

[Read more](#)

About AGE Reader technology

The AGE Reader technology is the answer to the need for measuring AGEs without the disadvantages of the existing methods. The AGE Reader technology is used in both the AGE Reader and Diab-spot. This state of art device provides a simple non-invasive solution that allows clinicians to determine the AGE level within 30 seconds.

[Read more](#)

Contact:

Bart van den Berg
Managing Director

tel: +31 (0)50 5890612
direct tel: +31 (0)6 54228480
e-mail:

DiagnOptics Technologies B.V.
L.J. Zielstraweg 1, Meditech Center
9713 GX Groningen
the Netherlands
www.diagnoptics.com